Novel veterinary medicines – how to make use of stem cells and monoclonal antibodies

The European Medicines Agency (EMA) is seeking feedback from its stakeholders on possible issues encountered when developing new veterinary medicines based on stem cells or monoclonal antibodies. Stakeholders are invited to comment on two problem statements that discuss questions around the development of veterinary medicines using these new technologies by 15 May 2016.

Click on this link for more information.